• 1
    Anderson DJ, Engemann JJ, Harrell LJ, Carmeli Y, Reller LB, Kaye KS. Predictors of mortality in patients with bloodstream infection due to ceftazidime-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother 2006; 50: 17151720.
  • 2
    Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003; 36: 5359.
  • 3
    Roberts RR, Hota B, Ahmad I et al. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin Infect Dis 2009; 49: 11751184.
  • 4
    Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118: 146155.
  • 5
    McGowan JJE. Resistance in nonfermenting gram-negative bacteria: multidrug resistance to the maximum. Am J Med 2006; 119 (suppl 1): 2936.
  • 6
    Bonomo RA, Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis 2006; 43 (suppl 2): 4956.
  • 7
    Pitout JDD, Laupland KB. Extended-spectrum [beta]-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008; 8: 159166.
  • 8
    European Centre for Disease Prevention and Control/European Medicines Agency. ECDC/EMEA joint technical report: the bacterial challenge: time to react.: European centre for disease prevention and control & European medicines agency, Stockholm, Sweden & London, United Kingdom, 2009.
  • 9
    Boucher HW, Talbot GH, Bradley JS et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 112.
  • 10
    Falagas ME, Koletsi PK, Bliziotis IA. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J Med Microbiol 2006; 55: 16191629.
  • 11
    Goossens H. Susceptibility of multi-drug-resistant Pseudomonas aeruginosa in intensive care units: results from the European MYSTIC study group. Clin Microbiol Infect 2003; 9: 980983.
  • 12
    Falagas ME, Karageorgopoulos DE. Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among gram-negative bacilli: need for international harmonization in terminology. Clin Infect Dis 2008; 46: 11211122.
  • 13
    Apisarnthanarak A, Pinitchai U, Thongphubeth K, Yuekyen C, Warren DK, Fraser VJ. A multifaceted intervention to reduce pandrug-resistant Acinetobacter baumannii colonization and infection in 3 intensive care units in a Thai tertiary care center: a 3-year study. Clin Infect Dis 2008; 47: 760767.
  • 14
    Doi Y, Husain S, Potoski BA, McCurry KR, Paterson DL. Extensively drug-resistant Acinetobacter baumannii. Emerg Infect Dis 2009; 15: 980982.
  • 15
    Park YK, Peck KR, Cheong HS, Chung DR, Song JH, Ko KS. Extreme drug resistance in Acinetobacter baumannii infections in intensive care units, South Korea. Emerg Infect Dis 2009; 15: 13251327.
  • 16
    Cohen AL, Calfee D, Fridkin SK et al. Recommendations for metrics for multidrug-resistant organisms in healthcare settings: SHEA/HICPAC Position paper. Infect Control Hosp Epidemiol 2008; 29: 901913.
  • 17
    Hidron AI, Edwards JR, Patel J et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007. Infect Control Hosp Epidemiol 2008; 29: 9961011.
  • 18
    Paterson David L, Doi Y. A step closer to extreme drug resistance (XDR) in gram-negative bacilli. Clin Infect Dis 2007; 45: 11791181.
  • 19
    Carmeli Y, Akova M, Cornaglia G et al. Controlling the spread of carbapenemase-producing Gram-negatives: therapeutic approach and infection control. Clin Microbiol Infect 2010; 16: 102111.
  • 20
    The Alliance for Prudent use of Antibiotics. Executive summary: select findings, conclusions, and policy recommendations. Clin Infect Dis 2005; 41 (suppl 4): 224227.
  • 21
    Jones RN, Masterton R. Determining the value of antimicrobial surveillance programs. Diagn Microbiol Infect Dis 2001; 41: 171175.
  • 22
    Tapsall JW, Ndowa F, Lewis DA, Unemo M. Meeting the public health challenge of multidrug- and extensively drug-resistant Neisseria gonorrhoeae. Expert Rev Anti Infect Ther 2009; 7: 821834.
  • 23
    Richter SS, Heilmann KP, Dohrn CL, Riahi F, Beekmann SE, Doern GV. Changing epidemiology of antimicrobial-resistant Streptococcus pneumoniae in the United States, 2004-2005. Clin Infect Dis 2009; 48: e23e33.
  • 24
    Parry CM, Threlfall EJ. Antimicrobial resistance in typhoidal and nontyphoidal salmonellae. Curr Opin Infect Dis 2008; 21: 531538, doi: 10.1097/QCO.0b013e32830f453a.
  • 25
    Hendriksen RS, Mikoleit M, Carlson VP et al. WHO Global Salm-Surv external quality assurance system for serotyping of Salmonella isolates from 2000 to 2007. J Clin Microbiol 2009; 47: 27292736.
  • 26
    Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; nineteenth informational supplement. CLSI document M100-S19, Wayne, Pa: Clinical and Laboratory Standards Institute, 2009; 29(3).
  • 27
    European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. 2008; Available at: (updated 27 April, 2010; last accessed 29 October, 2010).
  • 28
    MacGowan AP, on behalf of the BWPoRS. Clinical implications of antimicrobial resistance for therapy. J Antimicrob Chemother 2008; 62 (suppl 2): 105114.
  • 29
    Paterson DL. The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 2006; 43 (suppl 2): 4348.
  • 30
    Kallen AJ, Hidron AI, Patel J, Srinivasan A. Multidrug resistance among gram-negative pathogens that caused healthcare-associated infections reported to the National Healthcare Safety Network, 2006-2008. Infect Control Hosp Epidemiol 2010; 31: 528531.
  • 31
    Pillar CM, Draghi DC, Sheehan DJ, Sahm DF. Prevalence of multidrug-resistant, methicillin-resistant Staphylococcus aureus in the United States: findings of the stratified analysis of the 2004 to 2005 LEADER Surveillance Programs. Diagn Microbiol Infect Dis 2008; 60: 221224.
  • 32
    Seas C, Hernandez K, Ramos R et al. Oxacillin-resistant and multidrug-resistant Staphylococcus aureus in Lima, Peru. Infect Control Hosp Epidemiol 2006; 27: 198200.
  • 33
    Jeong HY, Lee JE, Choi BK et al. Molecular epidemiology of community-associated antimicrobial-resistant Staphylococcus aureus in Seoul, Korea (2003): pervasiveness of multidrug-resistant SCCmec type II methicillin-resistant S. aureus. Microb Drug Resist 2007; 13: 178185.
  • 34
    Critchley IA, Draghi DC, Sahm DF, Thornsberry C, Jones ME, Karlowsky JA. Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000–2001. J Antimicrob Chemother 2003; 51: 639649.
  • 35
    O’Fallon E, Gautam S, D’Agata EMC. Colonization with multidrug-resistant gram-negative bacteria: prolonged duration and frequent cocolonization. Clin Infect Dis 2009; 48: 13751381.
  • 36
    Andrade SS, Jones RN, Gales AC, Sader HS. Increasing prevalence of antimicrobial resistance among Pseudomonas aeruginosa isolates in Latin American medical centres: 5 year report of the SENTRY Antimicrobial Surveillance Program (1997–2001). J Antimicrob Chemother 2003; 52: 140141.
  • 37
    Gould IM. The epidemiology of antibiotic resistance. Int J Antimicrob Agents 2008; 32 (suppl 1): 29.
  • 38
    Siegel JD, Rhinehart E, Jackson M, Chiarello L. Management of multidrug-resistant organisms in health care settings, 2006. Am J Infect Control 2007; 35 (suppl 2): 165193.
  • 39
    Brink A, Feldman C, Richards G, Moolman J, Senekal M. Emergence of extensive drug resistance (XDR) among Gram-negative bacilli in South Africa looms nearer. S Afr Med J 2008; 98: 586, 8, 90 passim.
  • 40
    Tseng YC, Wang JT, Wu FL, Chen YC, Chie WC, Chang SC. Prognosis of adult patients with bacteremia caused by extensively resistant Acinetobacter baumannii. Diagn Microbiol Infect Dis 2007; 59: 181190.
  • 41
    CDC. Emergence of Mycobacterium tuberculosis with extensive resistsance to second-line drugs – Worldwide, 2000–2004. MMWR Morb Mortal Wkly Rep 2006; 55: 301305.
  • 42
    CDC. Notice to readers: revised definition of extensively drug-resistant tuberculosis. MMWR Morb Mortal Wkly Rep 2006; 55: 1176.
  • 43
    Kuo LC, Teng LJ, Yu CJ, Ho SW, Hsueh PR. Dissemination of a clone of unusual phenotype of pandrug-resistant Acinetobacter baumannii at a university hospital in Taiwan. J Clin Microbiol 2004; 42: 17591763.
  • 44
    Kuo LC, Yu CJ, Lee LN et al. Clinical features of pandrug-resistant Acinetobacter baumannii bacteremia at a university hospital in Taiwan. J Formos Med Assoc 2003; 102: 601606.
  • 45
    Ortega B, Groeneveld AB, Schultsz C. Endemic multidrug-resistant Pseudomonas aeruginosa in critically ill patients. Infect Control Hosp Epidemiol 2004; 25: 825831.
  • 46
    Lang BJ, Aaron SD, Ferris W, Hebert PC, MacDonald NE. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with multiresistant strains of Pseudomonas aeruginosa. Am J Respir Crit Care Med 2000; 162: 22412245.
  • 47
    Davies G, McShane D, Davies JC, Bush A. Multiresistant Pseudomonas aeruginosa in a pediatric cystic fibrosis center: natural history and implications for segregation. Pediatr Pulmonol 2003; 35: 253256.
  • 48
    Dubois V, Arpin C, Melon M et al. Nosocomial outbreak Due to a multiresistant strain of Pseudomonas aeruginosa P12: efficacy of cefepime-amikacin therapy and analysis of {beta}-lactam resistance. J Clin Microbiol 2001; 39: 20722078.
  • 49
    Pagani L, Colinon C, Migliavacca R et al. Nosocomial outbreak caused by multidrug-resistant Pseudomonas aeruginosa producing IMP-13 metallo-{beta}-Lactamase. J Clin Microbiol 2005; 43: 38243828.
  • 50
    Jung R, Fish DN, Obritsch MD, MacLaren R. Surveillance of multi-drug resistant Pseudomonas aeruginosa in an urban tertiary-care teaching hospital. J Hosp Infect 2004; 57: 105111.
  • 51
    European Committee on Antimicrobial Susceptibility Testing (EUCAST). Expert rules in antimicrobial susceptibility testing, 2008, Available from: (updated April, 2008; last accessed 28 October 2010)
  • 52
    Komp Lindgren P, Karlsson A, Hughes D. Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections. Antimicrob Agents Chemother 2003; 47: 32223232.
  • 53
    Leclercq R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin Infect Dis 2002; 34: 482492.